The Pfizer saga - Discussing the implications of Pfizer/Xalatan case in the EU

This webinar series focuses on key challenges facing companies in the life sciences sector in the fields of competition law, EU and national regulation, data protection, and anti-corruption. 

A discussion of the implications of the Pfizer/Xalatan case within the context of life cycle management strategies from a regulatory and competition law perspective.

Presented by: Andrea Zulli and Robin Blaney